Leko, VidMcDuffie, Lucas A.Zheng, ZhiliGartner, Jared J.Prickett, Todd D.Apolo, Andrea B.Agarwal, Piyush K.Rosenberg, Steven A.Lu, Yong-Chen2020-11-092020-11-092019-06-15Leko, V., McDuffie, L. A., Zheng, Z., Gartner, J. J., Prickett, T. D., Apolo, A. B., Agarwal, P. K., Rosenberg, S. A., & Lu, Y.-C. (2019). Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. The Journal of Immunology, 202(12), 3458–3467. https://doi.org/10.4049/jimmunol.18010220022-1767, 1550-6606https://hdl.handle.net/1805/24348Immune checkpoint inhibitors (ICIs) are effective in treating a variety of malignancies, including metastatic bladder cancer. A generally accepted hypothesis suggests that ICIs induce tumor regressions by reactivating a population of endogenous tumor-infiltrating lymphocytes (TILs) that recognize cancer neoantigens. Although previous studies have identified neoantigen-reactive TILs from several types of cancer, no study to date has shown whether or not neoantigen-reactive TILs can be found in bladder tumors. To address this, we generated TIL cultures from patients with primary bladder cancer and tested their ability to recognize tumor-specific mutations. We found that CD4+ TILs from one patient recognized mutated C-terminal binding protein 1 (CTBP1Q277R) in an MHC class II-restricted manner. This finding suggests that neoantigen-reactive TILs reside in bladder cancer, which may help explain the effectiveness of immune checkpoint blockade in this disease, and also provides a rationale for the future use of adoptive T-cell therapy targeting neoantigens in bladder cancer.en-USlymphocytesPrimary Bladder CancerImmune checkpoint inhibitorstumor-infiltrating lymphocytesArticle